POLR2A: A Potential Drug Target and Biomarker (G5430)

Target Name: POLR2A

NCBI ID: G5430

POLR2A

POLR2A: A Potential Drug Target and Biomarker

POLR2A (poly (A) rRNA-convertase 2A) is a non-coding RNA molecule that plays a crucial role in the regulation of gene expression in eukaryotic cells. It is a key enzyme in the poly (A) rRNA (POR) complex, which is responsible for converting pre-mRNA to functional RNA. POLR2A is expressed in most tissues and cells and is involved in the regulation of various cellular processes, including cell growth, apoptosis, and translation of RNA into proteins.

Drugs that target POLR2A have the potential to treat a wide range of diseases, including cancer, neurodegenerative diseases, and chronic obstructive pulmonary disease (COPD). As a drug target, POLR2A can be developed as a therapeutic target for small molecules, antibodies, or other therapeutic agents that can modulate its activity. As a biomarker, POLR2A can be used to diagnose and monitor diseases, including cancer, neurodegenerative diseases, and COPD.

POLR2A Structure and Function

POLR2A is a small non-coding RNA molecule that contains 214 amino acid residues. It has a distinct N-terminal region that contains a single nucleotide, a poly (A) rRNA-like structure, and a C-terminal region that contains a conserved GFP-like gene. The C-terminal region of POLR2A contains a unique feature, known as the NED domain, which is responsible for the stability and activity of the enzyme.

The NED domain is a conserved protein domain that is commonly found in RNA-protein interactions. It is involved in the formation of a stable complex between the enzyme and its target protein, as well as the regulation of the enzyme's activity. The NED domain is also involved in the regulation of the structure and stability of the enzyme.

POLR2A is a member of the PRIMER family of RNA-protein interactions, which are involved in the regulation of gene expression. The PRIMER family is composed of four subfamilies, including PRIMER1, PRIMER2, PRIMER3, and PRIMER4. These subfamilies are characterized by the presence of a specific protein domain, known as the PSS domain, which is responsible for the interaction between the enzyme and its target protein.

POLR2A is involved in the regulation of gene expression by the poly (A) rRNA (POR) complex. The POR complex is a complex that consists of several subunits, including the alpha subunit, the beta subunit, and the gamma subunit. The alpha subunit is the catalytic subunit and is responsible for the conversion of pre-mRNA to functional RNA. The beta and gamma subunits are non-catalytic subunits that are involved in the regulation of the activity of the alpha subunit.

The role of the POR complex is to regulate the expression of gene products by ensuring that only properly processed RNA is translated into proteins. The POR complex is activated by the binding of specific factors, including the protein factors that interact with the NED domain of the enzyme.

POLR2A is also involved in the regulation of apoptosis, which is a process that is responsible for the programmed cell death that occurs in eukaryotic cells. The regulation of apoptosis by the POR complex is thought to be involved in the development and progression of neurodegenerative diseases.

Drugs that target POLR2A have the potential to treat a wide range of diseases, including cancer, neurodegenerative diseases, and COPD. The use of such drugs would be

Protein Name: RNA Polymerase II Subunit A

Functions: DNA-dependent RNA polymerase catalyzes the transcription of DNA into RNA using the four ribonucleoside triphosphates as substrates. Largest and catalytic component of RNA polymerase II which synthesizes mRNA precursors and many functional non-coding RNAs. Forms the polymerase active center together with the second largest subunit. Pol II is the central component of the basal RNA polymerase II transcription machinery. It is composed of mobile elements that move relative to each other. RPB1 is part of the core element with the central large cleft, the clamp element that moves to open and close the cleft and the jaws that are thought to grab the incoming DNA template. At the start of transcription, a single-stranded DNA template strand of the promoter is positioned within the central active site cleft of Pol II. A bridging helix emanates from RPB1 and crosses the cleft near the catalytic site and is thought to promote translocation of Pol II by acting as a ratchet that moves the RNA-DNA hybrid through the active site by switching from straight to bent conformations at each step of nucleotide addition. During transcription elongation, Pol II moves on the template as the transcript elongates. Elongation is influenced by the phosphorylation status of the C-terminal domain (CTD) of Pol II largest subunit (RPB1), which serves as a platform for assembly of factors that regulate transcription initiation, elongation, termination and mRNA processing. Regulation of gene expression levels depends on the balance between methylation and acetylation levels of tha CTD-lysines (By similarity). Initiation or early elongation steps of transcription of growth-factors-induced immediate early genes are regulated by the acetylation status of the CTD (PubMed:24207025). Methylation and dimethylation have a repressive effect on target genes expression (By similarity)

The "POLR2A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about POLR2A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets